In English | En español

National Cancer Institute

at the National Institutes of Health

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI

Clinical Trials Search Results

Page Options

Email This Document

Clinical Trial Questions?
Get Help:
1-800-4-CANCER
LiveHelp online chat

Popular Resources

Help Using the NCI Clinical Trials Search Form
How to Find a Cancer Treatment Trial
Learn About Clinical Trials
About NCI's List of Cancer Clinical Trials
NCI Dictionary of Cancer Terms
NCI Drug Dictionary
Featured Clinical Trials Supported by NCI

View Content for:

Patients
Health Professionals

Display:

Title
Description with: Locations Eligibility
Full Trial Description
Custom

Results 1-25 of 52 for your search:

Cancer Type/Condition:  Neuroblastoma
Stage/Subtype:  recurrent neuroblastoma
Country:  U.S.A.
Trial Type:  Treatment
Trial Status:  Active

Hide Search Criteria

Show Search Criteria

Help with Results

Select All on Page Sort by: Show Results per Page

Reduced Intensity Transplant Using Extracorporeal Photopheresis

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and under
Sponsor: Pharmaceutical / Industry
Protocol IDs: ECP RIT, NCT00179790

Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral ß-glucan for High-Risk Neuroblastoma

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 21 and under
Sponsor: Other
Protocol IDs: 05-075, NCT00911560

Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 1 to 21
Sponsor: NCI, Other
Protocol IDs: CDR0000647587, COG-ADVL0912, ADVL0912, NCT00939770

A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 12 to 17
Sponsor: Pharmaceutical / Industry
Protocol IDs: CLDE225X2104, 2010-019348-37, NCT01125800

Allogeneic Tumor Cell Vaccination With Oral Metronomic Cytoxan in Patients With High-Risk Neuroblastoma

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 21 and under
Sponsor: Other
Protocol IDs: H-26652-ATOMIC, NCT01192555

To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 2 to 20
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: 100220, IND 59,056, NCT01222780

Clinical Study of Vorinostat in Combination With Etoposide in Pediatric Patients < 21 Years at Diagnosis With Refractory Solid Tumors

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 4 to 21
Sponsor: Other
Protocol IDs: 10-096, NCT01294670

Safety and Efficacy Study of TPI-287 in Neuroblastoma and Medulloblastoma

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Over 12 months to 30 years
Sponsor: Pharmaceutical / Industry
Protocol IDs: NMTRC 004, NCT01483820

Randomized Efficacy Study of TPI 287 to Treat Primary Refractory or Early Relapsed Neuroblastoma

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 12 to 21
Sponsor: Pharmaceutical / Industry
Protocol IDs: NMTRC 005, NCT01505608

10.

Study of MLN8237 in Combination With Irinotecan and Temozolomide

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 12 to 30
Sponsor: Other
Protocol IDs: N2009-03, NCT01601535

11.

Phase II Study of Umbilical Cord Blood as a Source of Hematopoietic Stem Cells for Transplantation in Children With Malignant or Non-Malignant Diseases. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information.

Phase: Phase II
Type: Treatment
Status: Active
Age: 21 and under
Sponsor: Other
Protocol IDs: PSCI-2003-232, NCT00084695

12.

Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma

Phase: Phase II
Type: Treatment
Status: Active
Age: Over 1
Sponsor: NCI, Other
Protocol IDs: 04-148, MSKCC-04148, NCT00107289

13.

Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Any age
Sponsor: Other
Protocol IDs: 05-122, MSKCC-05122, NCT00445965

14.

Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma

Phase: Phase II
Type: Treatment
Status: Active
Age: 21 and under
Sponsor: Pharmaceutical / Industry
Protocol IDs: V0706, NCT00601003

15.

Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant

Phase: Phase II
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: 2007LS072, UMN-MT2007-07, 0707M11845, UMN-2007LS072, NCT00617929

16.

Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 7176, NCI-2010-00509, NCT01110135

17.

Bevacizumab, Irinotecan and Temozolomide for Relapsed or Refractory Neuroblastoma

Phase: Phase II
Type: Treatment
Status: Active
Age: Any age
Sponsor: Other
Protocol IDs: 10-015, NCT01114555

18.

Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 1 to 21
Sponsor: NCI, Other
Protocol IDs: ADVL0921, NCI-2011-02051, CDR0000680512, U10CA098543, COG-ADVL0921, NCT01154816

19.

High-Dose 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Primary Refractory Neuroblastoma in Bone Marrow

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 months and over
Sponsor: Other
Protocol IDs: 09-161, NCT01183897

20.

Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 0 to 21
Sponsor: Other
Protocol IDs: 11-183, NCT01492673

21.

Preventative Trial of DFMO in Patients With High Risk Neuroblastoma in Remission

Phase: Phase II
Type: Treatment
Status: Active
Age: 21 and under
Sponsor: Pharmaceutical / Industry
Protocol IDs: NMTRC 003, NCT01586260

22.

A Phase II Trial of Reduced Intensity Conditioning and Haploidentical BMT for High-risk Solid Tumors

Phase: Phase II
Type: Treatment
Status: Active
Age: 0 to 40
Sponsor: Other
Protocol IDs: J12106, NCT01804634

23.

N99-02: Melphalan and Buthionine Sulfoximine Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Children With Resistant or Recurrent Neuroblastoma

Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Over 9 months to 30 years
Sponsor: NCI, Other
Protocol IDs: CDR0000067849, P01CA081403, NANT-99-02, 68, N99-02, CHLA-LA-NANT-99-02, CHLA-CCI-00.020, NCT00005835

24.

Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors

Phase: Phase I
Type: Treatment
Status: Active
Age: 2 to 25
Sponsor: NCI, Other
Protocol IDs: CDR0000257582, UIHC-200008086, NCI-V02-1710, 200008086, NCT00049023

25.

Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer

Phase: Phase I
Type: Treatment
Status: Active
Age: Any age
Sponsor: NCI, Other
Protocol IDs: 03-133, P30CA008748, MSKCC-03133, NCT00089245

Select All on Page

Help with Results

We Can Answer Your Questions
1-800-4-CANCER
LiveHelp Online Chat

NCI Home
Contact Us
Policies
Accessibility
Viewing Files
FOIA
Site Help
Site Map